Entrada Therapeutics Inc (TRDA)

In the past six months, Entrada Therapeutics' stock price has been impacted by inducement grants, financial results, recommendations regarding the ELEVATE-44-201 study, presentations at investor conferences, and insider selling. The company announced inducement grants in early March 2026. The company reported its fourth quarter and full-year 2025 financial results on February 26, 2026, which coincided with a +6.76% stock movement. The initiation of Cohort 2 at an increased dose in Entrada Therapeutics' ELEVATE-44-201 study was recommended on February 17, 2026, leading to a +1.29% change. Presentations at investor conferences led to an -8.23% decrease on February 4, 2026. Progress across its portfolio of RNA-based therapeutics resulted in a -2.14% change in January 2026. Insider selling by the company's COO and CFO in March 2026 also occurred. Over the past 12 months, the stock has gained 19.8%.

As a clinical-stage biotechnology company, Entrada Therapeutics does not generate revenue from commercial product sales. Its revenue is primarily derived from research and development activities, collaborations, licensing agreements, and grants. Therefore, demand seasonality is not applicable at this stage of the company's development.

Entrada Therapeutics is a clinical-stage biotechnology company focused on developing intracellular therapeutics using its proprietary Endosomal Escape Vehicle (EEV™) platform. The company's major product candidates are RNA-based oligonucleotide programs for Duchenne muscular dystrophy (DMD), targeting patients amenable to exon skipping. Entrada also has a partnered clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1), and ENTR-801 for Usher syndrome type 2A (USH2A). The company's primary revenue sources are research and development activities, collaborations, licensing agreements, and grants.

Entrada Therapeutics is headquartered in Boston, Massachusetts, United States, and maintains an international presence in the United Kingdom through Entrada Therapeutics (UK) Ltd. The company's operational footprint is primarily concentrated in these locations, while clinical trials may be conducted across multiple regions.

Entrada Therapeutics generally holds a positive brand reputation due to its innovative Endosomal Escape Vehicle (EEV™) platform. Analysts have given the company a consensus rating of "Moderate Buy," with an average rating score of 2.60. The company's ENTR-601-44 program has shown potential for superior dystrophin restoration compared to competitors. Potential risks to its reputation include clinical program failures, safety issues with its EEV technology, lower-than-anticipated efficacy in trials, and regulatory uncertainties.

Entrada Therapeutics has a mixed ownership structure with significant institutional and insider holdings. As of March 23, 2026, 158 institutional owners held 27,105,032 shares. Major institutional owners include Baker Bros. Advisors Lp, MPM Asset Management Llc, 5AM Venture Management, LLC, BlackRock, Inc., Vanguard Group Inc, Wellington Management Group Llp, StepStone Group LP, Geode Capital Management, Llc, State Street Corp, and Millennium Management Llc. 5am Ventures V LP and Kush Parmar each hold 13.55% of the shares. Institutional shareholders hold approximately 63.81% of the stock, Entrada Therapeutics insiders hold 89.58%, and retail investors hold 0.00% according to one source, while another indicates 17.40% institutional, 36.14% insiders, and 46.46% public/individual investors. Insider selling has outweighed buying in the past three months.